Clindamycin Phosphate And Benzoyl Peroxide Gel
NDC Package 45802-736-84
Package Information
Clindamycin Phosphate And Benzoyl Peroxide (clindamycin, benzoyl peroxide) gel is clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/5% is indicated for the topical treatment of inflammatory acne vulgaris in patients 12 years and older. This formulation utilizes a gel delivery system. Marketed by Padagis Israel Pharmaceuticals Ltd, this product is identified by NDC 45802-736 and is authorized under FDA application ANDA090979.
Identification & Billing
- RxCUI: 1540241 - clindamycin phosphate 1.2 % / benzoyl peroxide 5 % Topical Gel
- RxCUI: 1540241 - benzoyl peroxide 0.05 MG/MG / clindamycin phosphate 0.012 MG/MG Topical Gel
- RxCUI: 1540241 - benzoyl peroxide 5 % / clindamycin phosphate 1.2 % Topical Gel
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 45802 - Padagis Israel Pharmaceuticals Ltd
- 45802-736 - Clindamycin Phosphate And Benzoyl Peroxide
- 45802-736-84 - 1 TUBE in 1 CARTON / 45 g in 1 TUBE
- 45802-736 - Clindamycin Phosphate And Benzoyl Peroxide
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 45802-736-84 identifies a specific commercial package of 1 tube in 1 carton / 45 g in 1 tube of Clindamycin Phosphate And Benzoyl Peroxide, a human prescription drug labeled by Padagis Israel Pharmaceuticals Ltd. This gel is formulated for topical use and contains benzoyl peroxide; clindamycin phosphate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Padagis Israel Pharmaceuticals Ltd on June 26, 2012. The current certification is valid through December 31, 2026.
How is this Padagis Israel Pharmaceuticals Ltd product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 45802073684. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. There are 45 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.